Sarepta (SRPT) Could See Exon 53 Approval in 2018, Peak Sales of ~$800M - William Blair
Tweet Send to a Friend
William Blair analyst Tim Lugo weighed in on Sarepta Therapeutics (NASDAQ: SRPT) after the company announced positive interim 48-week data ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
